Literature DB >> 23242463

Preparation and pathogen inactivation of double dose buffy coat platelet products using the INTERCEPT blood system.

Mohammad R Abedi1, Ann-Charlotte Doverud.   

Abstract

Blood centers are faced with many challenges including maximizing production yield from the blood product donations they receive as well as ensuring the highest possible level of safety for transfusion patients, including protection from transfusion transmitted diseases. This must be accomplished in a fiscally responsible manner which minimizes operating expenses including consumables, equipment, waste, and personnel costs, among others. Several methods are available to produce platelet concentrates for transfusion. One of the most common is the buffy coat method in which a single therapeutic platelet unit (≥ 2.0 x10(11) platelets per unit or per local regulations) is prepared by pooling the buffy coat layer from up to six whole blood donations. A procedure for producing "double dose" whole blood derived platelets has only recently been developed. Presented here is a novel method for preparing double dose whole blood derived platelet concentrates from pools of 7 buffy coats and subsequently treating the double dose units with the INTERCEPT Blood System for pathogen inactivation. INTERCEPT was developed to inactivate viruses, bacteria, parasites, and contaminating donor white cells which may be present in donated blood. Pairing INTERCEPT with the double dose buffy coat method by utilizing the INTERCEPT Processing Set with Dual Storage Containers (the "DS set"), allows blood centers to treat each of their double dose units in a single pathogen inactivation processing set, thereby maximizing patient safety while minimizing costs. The double dose buffy coat method requires fewer buffy coats and reduces the use of consumables by up to 50% (e.g. pooling sets, filter sets, platelet additive solution, and sterile connection wafers) compared to preparation and treatment of single dose buffy coat platelet units. Other cost savings include less waste, less equipment maintenance, lower power requirements, reduced personnel time, and lower collection cost compared to the apheresis technique.

Entities:  

Mesh:

Year:  2012        PMID: 23242463      PMCID: PMC3607280          DOI: 10.3791/4414

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  8 in total

Review 1.  Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease.

Authors:  L Corash; L Lin
Journal:  Bone Marrow Transplant       Date:  2004-01       Impact factor: 5.483

2.  Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods.

Authors:  Walter Nussbaumer; Doris Allerstorfer; Doris Allersdorfer; Christoph Grabmer; Margaret Rheinschmidt; Lily Lin; Diether Schönitzer; Cornelia Lass-Flörl
Journal:  Transfusion       Date:  2007-07       Impact factor: 3.157

3.  Emerging infectious disease agents and their potential threat to transfusion safety.

Authors:  Susan L Stramer; F Blaine Hollinger; Louis M Katz; Steven Kleinman; Peyton S Metzel; Kay R Gregory; Roger Y Dodd
Journal:  Transfusion       Date:  2009-08       Impact factor: 3.157

4.  Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™

Authors:  Johannes Irsch; Lily Lin
Journal:  Transfus Med Hemother       Date:  2011-01-27       Impact factor: 3.747

5.  Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats.

Authors:  D J van Rhenen ; J Vermeij; V Mayaudon; C Hind; L Lin; L Corash
Journal:  Vox Sang       Date:  2000       Impact factor: 2.144

6.  Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.

Authors:  Lily Lin; Roberta Dikeman; Barbara Molini; Sheila A Lukehart; Robert Lane; Kent Dupuis; Peyton Metzel; Laurence Corash
Journal:  Transfusion       Date:  2004-10       Impact factor: 3.157

Review 7.  Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.

Authors:  Jean Pierre Allain; Celso Bianco; Morris A Blajchman; Mark E Brecher; Michael Busch; David Leiby; Lily Lin; Susan Stramer
Journal:  Transfus Med Rev       Date:  2005-04

8.  Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light.

Authors:  Lily Lin; Carl V Hanson; Harvey J Alter; Valérie Jauvin; Kristen A Bernard; Krishna K Murthy; Peyton Metzel; Laurence Corash
Journal:  Transfusion       Date:  2005-04       Impact factor: 3.157

  8 in total
  2 in total

Review 1.  Platelet MicroRNAs: An Overview.

Authors:  Neetu Dahiya; Tewarit Sarachana; Long Vu; Kevin G Becker; William H Wood; Yongqing Zhang; Chintamani D Atreya
Journal:  Transfus Med Rev       Date:  2015-08-10

2.  Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects.

Authors:  Konrad Rosskopf; Wolfgang Helmberg; Peter Schlenke
Journal:  Transfusion       Date:  2020-07-03       Impact factor: 3.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.